Stage III Colon Cancer: Can We Refine the Selection for Adjuvant Treatment?

Earn CME for related activities: hmpeducation.com/
In this webcast from the '2019 ESMO World Congress on Gastrointestinal Cancer', Dr. Alberto Sobrero discusses whether it is possible to further refine treatment selection for adjuvant therapy for patients with Stage III colon cancer.

[@khaliddurrani6432]

In the absence of liquid biopsy Stage 3 can be subdivided into low risk T1-3, N1 , intermediate risk T4a N1/2 and high risk T4b N2 . Low and intermediate risk patients may receive 3 months of capox, with only one fourth toxicity.